

去甲肾上腺素; 节后交感神经纤维; 组胺  $H_3$  受体; 高压液相色谱法

目的: 观察组胺  $H_3$  受体介导抑制心交感神经末梢释放去甲肾上腺素(NE)。方法: 采用 HPLC-ECD 法检测电场刺激(50 mA, 5 ms)诱发交感神经末梢

释放 NE。结果:  $\alpha$ -甲基组胺浓度依赖性抑制电场刺激诱发的 NE 释放。  $H_1$ ,  $H_2$ ,  $\alpha_2$ ,  $\beta_2$  受体拮抗剂不能拮抗  $\alpha$ -甲基组胺的作用。 Thioperamide 浓度依赖性拮抗  $\alpha$ -甲基组胺的作用。单独应用 thioperamide 可促进 NE 释放。结论: 突触前组胺  $H_3$  受体参与介导抑制心交感神经末梢释放 NE。

BIBLID: ISSN 0253-9756

Acta Pharmacologica Sinica 中国药理学报

1996 Sep; 17 (5); 428 - 431

## Effects of HI-6 on muscle acetylcholine receptor: analysis on minimal reaction model


CHEN Hou-Chang, BAI Dun-Yan<sup>1</sup>, JIANG Yi-Ping (Department of Pharmacology, <sup>1</sup>Department of Computer, First Military Medical University, Guangzhou 510515, China)

**KEY WORDS** HI-6; skeletal muscle; cholinergic receptors; messenger RNA; *Xenopus laevis*; oocytes

**AIM:** To study the action of 1-(2-hydroxyimino-methyl-1-pyridino)-3-(4-carbamoyl-1-pyridino)-2-oxapropane dichloride (HI-6) on skeletal muscle acetylcholine receptor ( $N_2$ -ChR). **METHODS:**  $N_2$ -ChR was expressed in *Xenopus laevis* oocyte after injection with mRNA extracted from denervated rat leg muscles. The inward membrane currents induced by various concentrations of carbamylcholine and effects of HI-6 or *d*-tubocurarine on the currents were measured with voltage clamp technique by fast cell flow of agents. The actions of HI-6 and *d*-tubocurarine on  $N_2$ -ChR were analyzed by using the minimal reaction model. **RESULTS:**  $K$  of 40.05, 156.00, and 334.67  $\mu\text{mol} \cdot \text{L}^{-1}$  for HI-6,  $K$  of 0.02, 0.10, and 0.18  $\mu\text{mol} \cdot \text{L}^{-1}$  for *d*-tubocurarine were obtained by using the competing for single acetylcholine (ACh)-binding site model, the competing for two ACh-binding sites model, and the noncompetitive inhibition model, respectively. **CONCLUSION:** HI-6 and *d*-tubocurarine competed for two ACh-binding sites of  $N_2$ -ChR with equal affinity to antagonize the effects of the agonist on  $N_2$ -ChR. The  $N_2$ -ChR inhibition by HI-6 is much

weaker than that by *d*-tubocurarine.

Oximes acetylcholinesterase reactivators such as 1-(2-hydroxyimino-methyl-1-pyridino)-3-(4-carbamoyl-1-pyridino)-2-oxapropane dichloride (HI-6) and 1,1'-[Oxybis(methylene)]bis-[(4-hydroxyimino)methyl]-pyridinium dichloride (obidoxime chloride) together with certain cholinergic blockers have been used effectively to antagonize organophosphorus agent (OP)-poisoning. However, the acetylcholinesterase reactivation mechanism alone is not sufficient to explain the antidotal effect of oximes against OP-induced toxicity<sup>[1]</sup>. Some other mechanisms such as antimuscarinic, ganglion-blocking, neuromuscular-blocking properties, and acetylcholinesterase-like activity may also contribute to their antidotal effect. The effects of oximes reactivators on  $N_2$ -ChR is quite complicated, including curarine-like inhibition<sup>[2]</sup>, noncompetitive antagonism of  $N_2$ -ChR and excitatory actions of  $N_2$ -ChR<sup>[3]</sup>



1-(2-Hydroxyimino-methyl-1-pyridino)-3-(4-carbamoyl-1-pyridino)-2-oxapropane dichloride (HI-6)

Received 1995-05-22

Accepted 1996-04-05

In the present study, the effects of HI-6 and *d*-tubocurarine on N<sub>2</sub>-ChR expressed in *Xenopus laevis* oocytes were investigated to reveal the mechanism of their action on N<sub>2</sub>-ChR.

## MATERIALS AND METHODS

**Expression of N<sub>2</sub>-ChR** N<sub>2</sub>-ChR mRNA was extracted from denervated *extensor digitorum longus* and *soleus* muscles of adult Wistar rat (Laboratory Center of this University)<sup>(4)</sup>. The oocytes were prepared from ♀ *Xenopus laevis* (Institute of Developmental Biology, Chinese Academy of Sciences) and injected with 20–50 nL of mRNA (0.8–1.0 g·L<sup>-1</sup>)<sup>(5)</sup> and incubated in Bath's solution containing streptomycin 50 mg·L<sup>-1</sup>, penicillin 100 kU·L<sup>-1</sup>, and 0.6% horse serum at 13–18 °C for 3–10 d.

**Measurement of membrane current** The inward membrane currents evoked by carbamylcholine were measured according to Ref 6 with slight modification: the agents were administered through a U-tube with one hole (200 μm in diameter).

To study the effects of HI-6 (Academy of Military Medical Science, China) and *d*-tubocurarine (Sigma) on carbamylcholine and minimize desensitization of N<sub>2</sub>-ChR caused by them, both were applied with carbamylcholine (Sigma) simultaneously.

**Data analysis** The responses induced by various concentrations of carbamylcholine were usually normalized to those at 5 mmol·L<sup>-1</sup>. The results were analysed according to the minimal reaction model<sup>(7-9)</sup>: in the absence of antagonist, the relationship between the peak current amplitude ( $\bar{I}$  and  $I$ ) evoked by agonist and  $L$  (ligand concentration) was given by Eq 1 and Eq 2. The value of 143 nA for  $I_M R_M$  was obtained by assuming the value of  $P_0$  as 0.7 at 5 mmol·L<sup>-1</sup> of carbamylcholine.

$$\bar{I} = \frac{I_M R_M L^2}{L^2(1 + \Phi) + 2K\Phi L + K^2\Phi} \quad (1)$$

$$I = \frac{I_M R_M L^2}{L^2(1 + \Phi) + 2K\Phi L + K^2\Phi} \cdot \frac{K_R}{K_R + L} \quad (2)$$

$$\bar{I}/I = 1 + L/K_R \quad (3)$$

Competitive inhibition model: (1) Competing for single ACh-binding site model: In the presence of competitive antagonist (B) assumed to bind one of the two ACh-binding sites with equal affinity, characterized by dissociation constant  $K_C$ , the relationship between  $I$  and  $L$  was given by Eq 4.

$$I_C = \frac{I_M R_M L^2}{L^2(1 + \Phi) + 2K\Phi L + K^2\Phi + (K\Phi L + K^2\Phi) \cdot B/K_C} \cdot \frac{K_R}{K_R + L} \quad (4)$$

$$\frac{I}{I_C} = 1 + \frac{B}{K_C} \cdot \frac{K\Phi L + K^2\Phi}{L^2(1 + \Phi) + 2K\Phi L + K^2\Phi} \quad (5)$$

(2) Competing for two ACh-binding sites model: In the

presence of the antagonist assumed to compete for two ACh-binding sites with equal affinity, characterized by the dissociation constant  $K_{2C}$ , the relationship between  $I$  and  $L$  was given by Eq 6.

$$I_{2C} = \frac{I_M R_M L^2}{L^2(1 + \Phi) + 2K\Phi L(1 + B/K_{2C}) + K^2\Phi(1 + B/K_{2C})^2} \cdot \frac{K_R}{K_R + L} \quad (6)$$

$$\frac{I}{I_{2C}} = 1 + \frac{2K\Phi L + 2K^2\Phi}{L^2(1 + \Phi) + 2K\Phi L + K^2\Phi} \cdot \frac{B}{K_{2C}} + \frac{K^2\Phi}{L^2(1 + \Phi) + 2K\Phi L + K^2\Phi} \cdot \left(\frac{B}{K_{2C}}\right)^2 \quad (7)$$

Noncompetitive inhibition model: The antagonist was assumed to bind a noncompetitive site distinct from the regulatory ACh-binding site, which was characterized by dissociation constant  $K_{NC}$ . Eq 8 was the expression for  $I$  for this mechanism.

$$I_{NC} = \frac{I_M R_M L^2}{(L^2(1 + \Phi) + 2K\Phi L + K^2\Phi)(1 + B/K_{NC})} \cdot \frac{K_R}{K_R + L} \quad (8)$$

$$I/I_{NC} = 1 + B/K_{NC} \quad (9)$$

## RESULTS

**Dose-dependence of response to carbamylcholine** At low carbamylcholine concentrations ( $L \ll K_R \leq 1 \text{ mmol} \cdot \text{L}^{-1}$ ), the regulatory inhibition effect could be neglected.  $K$  and  $\Phi$  value obtained from the linear fit of data in Fig 2 according to Eq 1 was 397.00 μmol·L<sup>-1</sup> and 0.38, respectively.  $K_R$  calculated by using Eq 3 and substituting known values of  $K$  and  $\Phi$  was 118.98 mmol·L<sup>-1</sup>. The dose-response curve (Fig 2 a) fitted by using Eq 2




Fig 1. Effects of *d*-tubocurarine (○) and HI-6 (●) on inward membrane current ( $I$ ) induced by carbamylcholine 1 mmol·L<sup>-1</sup>. a and c were linear fits of data (○) and (●), respectively. b and d were the best fits of data (○) and (●) respectively to Eq 7.  $n = 6$  cells.

was similar to that of ACh obtained from *torpedo* N<sub>2</sub>-ChR<sup>[8]</sup>.




Fig 2. Antagonistic models for *d*-tubocurarine and HI-6 induced by carbamylcholine in the absence (○) and presence (●) of antagonists, analysis on the basic minimal reaction model (a), analysis on competing for 2 ACh-binding sites model (b), for single ACh-binding site model (c), and on the noncompetitive inhibitory model (d).  $n = 6 - 8$  cells.

#### Mechanism of N<sub>2</sub>-ChR inhibition by HI-6

(1) Competing for single ACh-binding site model:  $K_C$  for *d*-tubocurarine and HI-6 were 0.02 and 40.05  $\mu\text{mol}\cdot\text{L}^{-1}$ , respectively, which were obtained by using the linear fit equations in Fig 1 (a) ( $I/I_T = 1 + 5.606B$ ) and (c) ( $I/I_H = 1 + 2.988B$ ) and eq 5 in which the expression had been reduced to the eq  $I/I_C = 1 + 0.121B/K_C$  by substituting known values of  $K$ ,  $\Phi$ , and  $L$  ( $1 \text{ mmol}\cdot\text{L}^{-1}$ ). The calculated concentration-response curves for carbamylcholine in the presence of *d*-tubocurarine  $0.2 \mu\text{mol}\cdot\text{L}^{-1}$  (Fig 2 I c) or HI-6  $0.2 \text{ mmol}\cdot\text{L}^{-1}$  (Fig 2 II c) obtained by using Eq 4 and substituting values of  $K$ ,  $\Phi$ ,  $K_R$ , and  $K_C$  were similar to curve a and the effects were diminished. Both curves were below data sets (Fig 2 I & II ●) at low carbamylcholine concentrations ( $< 20 \text{ mmol}\cdot\text{L}^{-1}$ ), respectively.

(2) Competing for two ACh-binding sites model: The curves in Fig 1 (b) and (d) represent the best fit of the data to Eq 7 (in which the expression had been reduced to the equation:  $I/I_{2C} = 1 + 0.241B/K_{2C} + 0.034 (B/K_{2C})^2$  by substituting known values of  $K$ ,  $\Phi$ , and  $L$  ( $1 \text{ mmol}\cdot\text{L}^{-1}$ ), where  $K_{2C}$  for *d*-tubocurarine and HI-6 was 0.10 and 156.00  $\mu\text{mol}\cdot\text{L}^{-1}$ , respectively. The calculated concentration-response curves for carbamylcholine in the presence of *d*-tubocurarine  $0.2 \mu\text{mol}\cdot\text{L}^{-1}$  (Fig 2 I b) and HI-6  $0.2 \text{ mmol}\cdot\text{L}^{-1}$  (Fig 2 II b) were obtained by using Eq 6 and substituting known values of  $K$ ,  $\Phi$ ,  $K_R$ , and  $K_{2C}$ . Two sets of data (Fig 2 I & II ●) fell on the two curves, respectively.

(3) Noncompetitive inhibition model: The  $K_{NC}$  for *d*-tubocurarine and HI-6 obtained by using the linear equations in Fig 1 (a) and (c) and Eq 9 was 0.18 and 334.67  $\mu\text{mol}\cdot\text{L}^{-1}$ , respectively. The calculated concentration-response curves for carbamylcholine in the presence of *d*-tubocurarine  $0.2 \mu\text{mol}\cdot\text{L}^{-1}$  (Fig 2 I d) and HI-6  $0.2 \text{ mmol}\cdot\text{L}^{-1}$  (Fig 2 II d) were obtained by using Eq 8 and substituting known values of  $K$ ,  $\Phi$ ,  $K_R$ , and  $K_{NC}$ . Neither of the data sets fell on the curves.

## DISCUSSION

In this paper, N<sub>2</sub>-ChR expressed in oocytes was used to probe the effects of HI-6 and *d*-tubocurarine. The results that the concentration-dependences to carbamylcholine in the presence of HI-6 or *d*-tubocurarine are similar and parallel shift to right from those in the absence of them suggest that both are the competitive antagonists of N<sub>2</sub>-ChR. The good fit of the experimental data to the equation for competing for two ACh-binding sites model rather than the other two models indicates that both HI-6 and *d*-tubocurarine bind two competitive ACh-binding sites of N<sub>2</sub>-ChR with equal affinity to antagonize the effect of carbamylcholine on N<sub>2</sub>-ChR. The much smaller  $K$  for *d*-tubocurarine than that for HI-6 indicates that the competitive inhibition of HI-6 on N<sub>2</sub>-ChR is much weaker than *d*-tubocurarine.

## REFERENCES

- 1 Su CT, Wang PH, Liu RF, Shib JH, Ma C, Lin CH, et al

- Kinetic studies and structure-activity relationships of bispyridinium oximes as reactivators of acetylcholinesterase inhibited by organophosphate compounds. *Fundam Appl Toxicol* 1986; 6: 506-14.
- 2 Caratsch CG, Waser PG. Effects of obidoxime chloride on native and sarin-poisoned frog neuromuscular junctions. *Pflügers Arch* 1984; 401: 84-90.
- 3 Alkondon M, Rao KS, Albuquerque EX. Acetylcholinesterase reactivators modify the functional properties of the nicotinic acetylcholine receptor ion channel. *J Pharmacol Exp Ther* 1988; 245: 543-56.
- 4 Methfessel C, Witzemann V, Takahashi T, Mishina M, Numa S, Sakmann B. Patch clamp measurements on *Xenopus laevis* oocytes: currents through endogenous channels and implanted acetylcholine receptor and sodium channels. *Pflügers Arch* 1986; 407: 577-88.
- 5 Aoshima H. Acetylcholine receptor-mediated membrane current in oocytes injected with *Electrophorus electricus* mRNA: analyses of nicotine, succinylcholine, and decamethonium responses on the basis of the minimal model. *J Biochem (Tokyo)* 1990; 108: 947-53.
- 6 Chen HC, Hess GP. Expression and characteristics of nicotinic receptors in *Xenopus* oocytes. *Chin J Pharmacol Toxicol* 1994; 8: 110-3.
- 7 Udgaonkar JB, Hess GP. Chemical kinetic measurements of a mammalian acetylcholine receptor by a fast-reaction technique. *Proc Natl Acad Sci USA* 1987; 84: 8758-62.
- 8 Takeyasu K, Shiono S, Udgaonkar JB, Fujita N, Hess GP. Acetylcholine receptor: characterization of the voltage-dependent regulatory (inhibitory) site for acetylcholine in membrane vesicles from *Torpedo californica* electroplax. *Biochemistry* 1986; 25: 1770-6.
- 9 Karpen JW, Hess GP. Acetylcholine receptor inhibition by *d*-tubocurarine involves both a competitive and a noncompetitive binding site as determined by stopped-flow measurements of receptor-controlled ion flux in membrane vesicles. *Biochemistry* 1986; 25: 1786-92.
- 428-431  
以最小反应模型分析 HI-6 抗骨骼肌烟碱受体的作用  
R966  
陈厚昌, 白敦衍<sup>1</sup>, 蒋毅萍  
R971  
(第一军医大学药理教研室, <sup>1</sup> 计算机教研室, 广州 510515, 中国)
- 关键词 HI-6; 骨骼肌; 胆碱能受体; 信使 RNA; 非洲爪蟾; 卵母细胞
- 目的: 研究 1-(2-hydroxyiminomethyl-1-pyridino)-3-(4-carbamoyl-1-pyridino)-2-oxapropane dichloride (HI-6) 拮抗骨骼肌烟碱受体 ( $N_2$ -ChR) 的机制. 方法: 将去神经大鼠小腿骨骼肌  $N_2$ -ChR 的 mRNA 注射入非洲爪蟾卵母细胞, 表达出功能性  $N_2$ -ChR. 以全细胞电压钳和快速全细胞灌流法测定不同浓度氨甲酰胆碱激动  $N_2$ -ChR 产生的内向跨膜电流, 以及 HI-6 和筒箭毒碱对其作用的影响. 以最小反应模型分析 HI-6 和筒箭毒碱抗  $N_2$ -ChR 的机制. 结果: 分别以竞争双乙酰胆碱结合位点模型, 竞争单乙酰胆碱结合位点模型和非竞争性抑制模型分析 HI-6 所得  $K$  值分别为 156.00, 40.05 和 334.67  $\mu\text{mol}\cdot\text{L}^{-1}$ , 筒箭毒碱的  $K$  值分别为 0.10, 0.02 和 0.18  $\mu\text{mol}\cdot\text{L}^{-1}$ . 实验所得数据与各模型的配合程度, 以竞争双乙酰胆碱结合位点模型最好, 而非竞争性抑制模型最差. 结论: HI-6 与筒箭毒碱属竞争性拮抗作用, 尤以竞争双乙酰胆碱结合位点机制更合适, 但前者的拮抗作用远较后者弱.

## Information for authors

Acta Pharmacologica Sinica 1996 Jan; 17 (1): 89-96

Br Med J 1991 Feb 9; 301 (6772): 338-41

N Engl J Med 1991 Feb 7; 324 (6): 424-8

Reprints of any article published in Acta Pharmacologica Sinica may be purchased from the Institute for Scientific Information, 3501 Market Street, Philadelphia PA 19104, USA.

Fax: 1-215-386-6362. Phone: 1-215-386-0100.